Cingulate Inc (CING)
NASDAQ:CING
Want to see CING full AI Analyst Report?
Top Page
Cingulate Inc
(NASDAQ:CING)
Select Model
Select Model
Rating:41Neutral
Price Target:
$3.50
▼(-35.78% Downside)
Action:Reiterated
Date:06/03/26
Overall score reflects high risk driven primarily by weak financial performance (no revenue, ongoing losses, cash burn and leverage concerns) and bearish technical momentum. Corporate events add uncertainty via the FDA delay and potential dilution from the ATM program, while valuation provides limited support due to ongoing losses.
Positive Factors
Lead ADHD program and platform focus
Cingulate’s lead program CTx-1301 targets ADHD with a once‑daily dexmethylphenidate formulation and the company highlights a large, growing ADHD market. A differentiated once‑daily CNS product and platform focus support durable commercial potential if regulatory and CMC issues are resolved.
Negative Factors
No revenue and persistent operating losses
Cingulate reports no product revenue and multi‑year operating losses (roughly $15M–$24M annually), implying continued reliance on external financing. Persistent negative operating and free cash flow limit internal funding for development and raise the probability of future dilutive financings, constraining long‑term autonomy.
Read all positive and negative factors
Positive Factors
Negative Factors
Lead ADHD program and platform focus
Cingulate’s lead program CTx-1301 targets ADHD with a once‑daily dexmethylphenidate formulation and the company highlights a large, growing ADHD market. A differentiated once‑daily CNS product and platform focus support durable commercial potential if regulatory and CMC issues are resolved.
Read all positive factors
Cingulate Inc (CING) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$54.28M
Dividend YieldN/A
Average Volume (3M)190.99K
Price to Earnings (P/E)―
Beta (1Y)5.23
Revenue GrowthN/A
EPS Growth58.01%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.26
Shares Outstanding13,469,036
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$23.25Price Target Upside326.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.46
Revenue Forecast (FY)$3.63M
Cingulate Inc Business Overview & Revenue Model
Company Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), wh...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Cingulate Inc. does not have publicly available information indicating material recurring revenue from commercial product sales. The company’s funding and potential future revenue model is expected to...
Cingulate Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -23.66M | -19.40M | -14.99M | -22.18M | -17.11M | -19.97M |
| Net Income | -27.71M | -22.45M | -16.56M | -23.53M | -17.68M | -20.71M |
Balance Sheet | ||||||
| Total Assets | 30.86M | 15.07M | 14.86M | 3.49M | 11.41M | 22.89M |
| Cash, Cash Equivalents and Short-Term Investments | 25.89M | 10.95M | 12.21M | 52.42K | 5.36M | 16.49M |
| Total Debt | 7.43M | 8.79M | 5.10M | 3.51M | 5.87M | 1.19M |
| Total Liabilities | 12.00M | 12.56M | 7.41M | 10.36M | 7.52M | 2.04M |
| Stockholders Equity | 18.86M | 2.51M | 7.46M | -6.87M | 3.88M | 20.84M |
Cash Flow | ||||||
| Free Cash Flow | -19.77M | -17.41M | -18.66M | -15.26M | -16.04M | -11.25M |
| Operating Cash Flow | -19.55M | -17.25M | -18.45M | -15.03M | -15.88M | -10.43M |
| Investing Cash Flow | -223.32K | -162.00K | -211.80K | -224.10K | -152.65K | -814.74K |
| Financing Cash Flow | 36.15M | 16.15M | 30.82M | 9.95M | 4.90M | 26.54M |
Cingulate Inc Technical Analysis
Neutral
5.45
Price Trends
5.25
Negative
5.90
Negative
4.91
Negative
Market Momentum
-0.31
Negative
51.57
Neutral
50.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CING, the sentiment is Neutral. The current price of 5.45 is above the 20-day moving average (MA) of 4.60, above the 50-day MA of 5.25, and above the 200-day MA of 4.91, indicating a neutral trend. The MACD of -0.31 indicates Negative momentum. The RSI at 51.57 is Neutral, neither overbought nor oversold. The STOCH value of 50.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CING.
Cingulate Inc Risk Analysis
Cingulate Inc disclosed 81 risk factors in its most recent earnings report. Cingulate Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cingulate Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $36.22M | -4.03 | >-0.01% | ― | ― | 37.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $6.02M | -1.86 | -226.28% | 10.27% | 10792.86% | 99.40% | |
44 Neutral | $204.87M | 0.03 | 248.08% | ― | ― | ― | |
44 Neutral | $32.12M | -0.58 | -53.60% | ― | ― | 15.42% | |
42 Neutral | $5.47M | -0.13 | -1292.87% | ― | ― | -72.78% | |
41 Neutral | $54.28M | -1.72 | -365.16% | ― | ― | 58.01% |
* Healthcare Sector Average
CING
Cingulate Inc
4.88
0.64
15.09%
BGMS
Bio Green Med Solution
1.06
-20.69
-95.13%
NNVC
NanoViricides
1.51
-0.06
-3.82%
ENLV
Enlivex
0.85
-0.08
-8.60%
FBLG
FibroBiologics, Inc.
1.07
-15.93
-93.70%
BOLD
Boundless Bio Inc.
1.44
0.26
22.03%
Cingulate Inc Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Cingulate Faces FDA Delay But Maintains ADHD Drug Plans
Negative
Jun 2, 2026
On June 2, 2026, Cingulate announced that the U.S. Food and Drug Administration issued a Complete Response Letter for the New Drug Application of CTx-1301, its once-daily dexmethylphenidate tablet for ADHD, following an October 2025 acceptance of ...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Cingulate Reshapes Board Structure and Leadership Roles
Neutral
May 19, 2026
Cingulate Inc. announced changes to its board structure as part of an effort to streamline governance, with Class II directors Jeff Ervin and Jay Roberts deciding not to seek re-election when their terms end at the 2026 Annual Meeting of Stockhold...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Cingulate Adds Independent Director Jiang to Board Committees
Positive
Apr 2, 2026
On March 27, 2026, Cingulate Inc. appointed Zhanpeng “Frederick” Jiang to its Board of Directors as a Class I director, with a term running until the 2028 annual stockholders’ meeting, subject to standard conditions. The appointm...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Cingulate Announces ATM Equity Program and Share Issuance
Positive
Mar 24, 2026
On March 24, 2026, Cingulate Inc. entered into an at-the-market sales agreement with A.G.P./Alliance Global Partners, allowing the company to issue and sell up to $100 million of common stock from time to time under an existing shelf registration....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.